• share
• favorite_border

鈥� Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress for CAR T cell therapy in solid tumors 鈥� One patient experienced a complete response, and one patient had a partial response 鈥� This type of cancer has limited treatment options, and most patients have a poor prognosis of six months or less 鈥� AIC100 is a CAR T cell therapy that targets the ICAM-1 protein on tumor cells

• share
• favorite_border

A new liquid biopsy approach developed by聽Johns Hopkins Kimmel Cancer Center investigators could revolutionize brain cancer detection by identifying circulating DNA fragments from tumors and immune cells in blood samples, potentially enabling earlier diagnosis.

• share
• favorite_border

The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to 鈥淏linatumomab in Childhood Standard-Risk B-Cell Acute Lymphoblastic Leukemia.鈥�

• share
• favorite_border

A satisfying intimate relationship may help diminish chemotherapy-related cognitive problems experienced by patients with breast cancer, a new study suggests.

• share
• favorite_border

A new collaboration bringing entrepreneurs and investors together with physician-scientists, surgeons, and medical technologists promises to launch the Baltimore region as a major national hub for new biomedical ventures and start-up companies.

• share
• favorite_border

Today, Penn Medicine celebrated the groundbreaking of the Roberts Proton Therapy Center at Penn Presbyterian Medical Center in University City, which is expected to open for patient care in late 2027.

• share
• favorite_border

How did horses become some of the greatest athletes in the animal kingdom? Researchers at Johns Hopkins Medicine may have found the answer, pinpointing a genetic mutation and evolutionary process that occurred millions of years ago, which appears to have optimized horses鈥� speeds and stamina.

• share
• favorite_border

鈥� Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer

• share
• favorite_border

A recent study reveals that dimethyl fumarate (DMF), a compound already approved for other inflammatory diseases, can prevent and alleviate periodontal tissue damage. The research demonstrates that DMF significantly shifts immune cell behavior, promoting anti-inflammatory macrophages and restoring mitochondrial health by enhancing mitophagy鈥攁 cellular process that removes damaged mitochondria. The drug achieves this through regulation of Tu translation elongation factor (TUFM), a protein critical to mitochondrial function. This breakthrough suggests a new therapeutic approach for periodontitis by targeting mitochondrial quality control and immune modulation rather than relying solely on traditional plaque-removal strategies.

• share
• favorite_border

UCLA researchers demonstrated that a novel topical BRAF inhibitor gel called LUT014 significantly reduces the severity of an acne-like rash, a common and painful side effect experienced by patients undergoing anti-EGFR therapies for colorectal cancer.

• share
• favorite_border

Ludwig Cancer Research released today the full scope of research to be presented by Ludwig-affiliated scientists at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held online and in person in Chicago, from April 25 to April 30.

• share
• favorite_border

...